ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 863

Contribution of MPO-/PR3-ANCA Tests to the Diagnosis of ANCA-Associated Vasculitis in a Community Hospital: Evaluation of 2,782 Samples

Eishi Uechi, Chiai Nakata, Tomoo Murayama and Yoshiki Shiohira, Rheumatology, Tomishiro Central Hospital, Okinawa, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ANCA and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The purpose of this study was to evaluate the contribution of MPO-/PR3-ANCA tests to the diagnosis of ANCA-associated vasculitis (AAV).

Methods:

We extracted patients who underwent MPO-/PR3-ANCA tests during the 5-year period from June 2009 to July 2014 using an electronic medical record system of a general hospital that has Departments of Rheumatology, Nephrology, Respiratory Diseases, Neurology, Cardiology, General Internal Medicine, and Dermatology in Okinawa, Japan. In the extracted patients, the clinical diagnosis and patients’ background were confirmed using this system.

Results:

From June 2009 to July 2014, 2,782 samples obtained from 2,019 subjects were presented to the MPO-ANCA and PR3-ANCA tests (CLEIA method). MPO-ANCA and PR3-ANCA were positive in 107 (5%) and 36 (2%) subjects, respectively, of whom 50 (48.0%) and 3 (8.3%), respectively, had AAV, and 12 (11.2%) and 12 (33.3%), respectively, had infection. In the MPO-ANCA-positive patients, those with AAV showed a significantly higher MPO-ANCA level than the non-AAV patients (p = 0.001). In the PR3-ANCA-positive patients, the PR3-ANCA level did not differ between AAV and non-AAV patients. In this study, the sensitivity, specificity, positive predictive value, and negative predictive value of the MPO-ANCA test in AAV diagnosis were 0.85, 0.69, 0.47, and 0.93, respectively, and those of the PR3-ANCA test were 0.25, 0.79, 0.08, and 0.93, respectively.

Conclusion:

In daily practice in the Department of Rheumatology and the other departments, many samples had been presented for MPO-/PR3-ANCA tests. However, the percentage of patients positive for each test was low (< 10%). In this study, the positive predictive values of both MPO-ANCA and PR3-ANCA tests were low. Most ANCA-positive patients had diseases other than AAV, including many with infection. These results suggest that the results of the ANCA tests in daily practice should be carefully interpreted, and differential diagnosis between AAV and other diseases such as infection is important. The MPO-ANCA level was higher in the AAV group than in the non-AAV group. However, both the MPO-ANCA and PR3-ANCA values markedly varied in each group, and AAV diagnosis based on the ANCA level was difficult. In a previous large-scale study, the sensitivity and specificity of the MPO-ANCA test for MPA were 58 and 91%, respectively, and those of the PR3-ANCA test for GPA were 65-67 and 86-89%, respectively. The low specificity of the MPO-ANCA test based on data in this hospital suggests the presence of many patients with ANCA-negative MPA. In addition, compared with the previous study, the sensitivity and positive predictive value of PR3-ANCA were extremely low. These results may reflect the low prevalence of GPA in Japan.When samples are presented for ANCA tests, patients in whom the pre-test probability of AAV is high should be selected, and the results of the test should be carefully interpreted even when samples are positive.


Disclosure: E. Uechi, None; C. Nakata, None; T. Murayama, None; Y. Shiohira, None.

To cite this abstract in AMA style:

Uechi E, Nakata C, Murayama T, Shiohira Y. Contribution of MPO-/PR3-ANCA Tests to the Diagnosis of ANCA-Associated Vasculitis in a Community Hospital: Evaluation of 2,782 Samples [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/contribution-of-mpo-pr3-anca-tests-to-the-diagnosis-of-anca-associated-vasculitis-in-a-community-hospital-evaluation-of-2782-samples/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contribution-of-mpo-pr3-anca-tests-to-the-diagnosis-of-anca-associated-vasculitis-in-a-community-hospital-evaluation-of-2782-samples/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology